- Home
- NIVF vs MIRA Comparison
NIVF vs MIRA Comparison
Compare NIVF & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- MIRA
- Stock Information
- Founded
- NIVF 2011
- MIRA 2020
- Country
- NIVF Thailand
- MIRA United States
- Employees
- NIVF N/A
- MIRA N/A
- Industry
- NIVF
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- MIRA Health Care
- Exchange
- NIVF NYSE
- MIRA Nasdaq
- Market Cap
- NIVF 12.2M
- MIRA 17.1M
- IPO Year
- NIVF N/A
- MIRA 2023
- Fundamental
- Price
- NIVF $1.16
- MIRA $1.05
- Analyst Decision
- NIVF
- MIRA Strong Buy
- Analyst Count
- NIVF 0
- MIRA 2
- Target Price
- NIVF N/A
- MIRA $14.00
- AVG Volume (30 Days)
- NIVF 11.9M
- MIRA 552.1K
- Earning Date
- NIVF 11-16-2024
- MIRA 11-11-2024
- Dividend Yield
- NIVF N/A
- MIRA N/A
- EPS Growth
- NIVF N/A
- MIRA N/A
- EPS
- NIVF 0.21
- MIRA N/A
- Revenue
- NIVF $5,136,153.00
- MIRA N/A
- Revenue This Year
- NIVF N/A
- MIRA N/A
- Revenue Next Year
- NIVF N/A
- MIRA N/A
- P/E Ratio
- NIVF $5.39
- MIRA N/A
- Revenue Growth
- NIVF N/A
- MIRA N/A
- 52 Week Low
- NIVF $0.55
- MIRA $0.51
- 52 Week High
- NIVF $17.24
- MIRA $6.40
- Technical
- Relative Strength Index (RSI)
- NIVF 56.42
- MIRA 38.97
- Support Level
- NIVF $1.07
- MIRA $1.04
- Resistance Level
- NIVF $3.28
- MIRA $1.20
- Average True Range (ATR)
- NIVF 0.42
- MIRA 0.07
- MACD
- NIVF 0.05
- MIRA 0.02
- Stochastic Oscillator
- NIVF 22.42
- MIRA 19.44
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.